• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Hopfield Jessica exercised 5,235 shares at a strike of $28.87 and sold $1,662,322 worth of shares (5,235 units at $317.54) (SEC Form 4)

    5/14/25 4:15:23 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care
    Get the next $PODD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hopfield Jessica

    (Last) (First) (Middle)
    C/O INSULET CORPORATION
    100 NAGOG PARK

    (Street)
    ACTON MA 01720

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    INSULET CORP [ PODD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/13/2025 M 5,235 A $28.87 32,152 D
    Common Stock 05/13/2025 S 5,235 D $317.54 26,917 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $28.87 05/13/2025 M 5,235 04/30/2017(1) 05/11/2026 Common Stock 5,235 $0 0 D
    Explanation of Responses:
    1. This option, which is fully vested, vested over a three-year period, with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant.
    /s/ Patricia K. Dolan, attorney-in-fact 05/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PODD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PODD

    DatePrice TargetRatingAnalyst
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    3/6/2025$340.00Outperform
    RBC Capital Mkts
    11/6/2024$300.00Outperform
    Bernstein
    5/30/2024$235.00Buy
    Redburn Atlantic
    5/7/2024$200.00Peer Perform → Outperform
    Wolfe Research
    12/21/2023$180.00 → $238.00Neutral → Outperform
    Robert W. Baird
    12/4/2023$185.00 → $234.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      11/12/24 12:53:28 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      10/7/24 11:37:08 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Insulet Corporation (Amendment)

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      2/13/24 5:06:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Financials

    Live finance-specific insights

    See more
    • Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

      Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

      5/8/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2025 on May 8, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-210

      4/3/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year

      Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 an

      2/20/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      8/29/24 4:17:26 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

      4 - INSULET CORP (0001145197) (Issuer)

      9/21/23 4:48:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Announces Publication of 2024 Sustainability Report

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is proud to announce the publication of its 2024 Sustainability Report. This report underscores Insulet's unwavering commitment to sustainable practices and highlights significant achievements in environmental, social, and governance (ESG) initiatives. "At Insulet, our sustainability impact is inextricably tied to our mission as a company and our workplace culture. Through our products and innovative business models, we can make life simpler for millions of people with diabetes while improving health outcomes," said Vice President of Global

      5/13/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

      Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

      5/8/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and General Counsel Kapples John W. exercised 5,278 shares at a strike of $95.43 and sold $1,680,885 worth of shares (5,278 units at $318.47) (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      5/15/25 4:25:39 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • President and CEO Mcevoy Ashley was granted 9,540 shares (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      5/15/25 4:24:25 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Director Hopfield Jessica exercised 5,235 shares at a strike of $28.87 and sold $1,662,322 worth of shares (5,235 units at $317.54) (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      5/14/25 4:15:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Insulet upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00

      5/13/25 8:51:02 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet downgraded by Wolfe Research

      Wolfe Research downgraded Insulet from Outperform to Peer Perform

      4/29/25 8:07:24 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • RBC Capital Mkts initiated coverage on Insulet with a new price target

      RBC Capital Mkts initiated coverage of Insulet with a rating of Outperform and set a new price target of $340.00

      3/6/25 7:30:36 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $PODD
    Leadership Updates

    Live Leadership Updates

    See more
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Host Investor Day on June 5, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company

      3/11/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $PODD
    SEC Filings

    See more
    • Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INSULET CORP (0001145197) (Filer)

      5/8/25 4:02:51 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Insulet Corporation

      DEF 14A - INSULET CORP (0001145197) (Filer)

      4/29/25 4:05:45 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Corporation filed SEC Form 8-K: Leadership Update

      8-K - INSULET CORP (0001145197) (Filer)

      4/28/25 4:13:09 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care